MAR 16, 2018 10:21 PM PDT

The 'Triple Pill': A New Blood Pressure Treatment

WRITTEN BY: Nouran Amin

Even though there exists an abundance of blood pressure-lowering drugs, high blood pressure persists to be a health concern not only in the US but globally. Blood pressure can lead to heart attacks, kidney issues, as well as stroke; therefore, treating blood pressure is a crucial priority. On a global level, many suffering from high blood-pressure do not get the treatment they need. Many blood-pressure drugs require more than one medication of the treatment regimen. Unfortunately, this increases the complexity of the treatment process causing patients to forget to take their multiple blood-pressure medications.

To fix this issue, a study examined the efficacy of three drugs combined as one combination pill in treating blood pressure and compared these results in usual treatment care. The clinical trial performed was known as the TRIUMPH trial and was conducted in Sri Lanka on patients that have untreated high blood pressure with some having diabetes as well as chronic kidney disease.

Patients enrolled in the study have received either the usual blood pressure care or the combination pill. The combination pill better known as the ‘Triple Pill’ contains three blood pressure drugs: telmisartan, amlodipine, and chlorthalidone. These drugs utilize different blood-pressure reduction mechanisms but, they all work to relax the blood vessels.

The crucial difference between the two categories (triple pill vs. usual care) was the time it took to see results. Patients in the ‘usual care’ category took a longer time to achieve a health blood-pressure target in comparison to the patient receiving the Triple Pill. "Most people — 70 percent — reached blood pressure targets with the Triple Pill,” said study lead author Ruth Webster, MD, of The George Institute for Global Health. “The benefits were seen straight away and maintained until six months, whereas with usual care control rates were 55 percent at six months and even lower earlier in the trial."

Each of the drug used in the Triple Pill was in low dose but effective individually in reducing blood pressure. The particular use of each of these drugs was effective in preventing blood-pressure-related deaths and heart disease. When combining these drugs in the Triple Pill, studies showed that it results in synergistic effects.

The most appealing part of developing the Triple Pill is it’s accessibility in low-income areas as well globally in impoverished areas. It was evaluated as a new tool for care in a real-world setting. "The most urgent need for innovative strategies to control blood pressure is in low- and middle-income countries," says Webster. "The Triple Pill approach is an opportunity to 'leap frog' over traditional approaches to care and adopt an innovative approach that has been shown to be effective."

Lead researchers will conduct a follow-up qualitative study on thoughts concerning the Triple Pill. They will also examine the cost-effectiveness to evaluate if the Triple Pill is a cost-effective solution for controlling blood pressure. Furthermore, if the Triple Pill will serve as a global healthcare drug, then it is important to note that every nation varies on what they consider as a healthy blood pressure target.

Sources: American College of Cardiology, Science Daily

 

About the Author
  • Nouran earned her BS and MS in Biology at IUPUI and currently shares her love of science by teaching. She enjoys writing on various topics as well including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
APR 21, 2020
Drug Discovery & Development
APR 21, 2020
Researchers Develop COVID-19 Nasal Spray Vaccine
Researchers from the University of Waterloo in Canada are working on a DNA-based vaccine for COVID-19 that can be applie ...
APR 17, 2020
Drug Discovery & Development
APR 17, 2020
Overcoming Multi-Drug Resistance in Cancer
Resistance to chemotherapeutic use in caner patients is something that is inevitable. Continued resistance to these drug ...
APR 27, 2020
Cancer
APR 27, 2020
The Tumor Suppressor and its Regulator: An Indirect Oncogene
Oncogenes, mutations in genes that promote cancer growth, have long been easy targets for cancer research due to the dir ...
APR 30, 2020
Drug Discovery & Development
APR 30, 2020
Researchers Use AI to Accelerate COVID-19 Drug Development
Researchers from the National University of Singapore (NUS) have developed an artificial intelligence platform to accele ...
MAY 25, 2020
Genetics & Genomics
MAY 25, 2020
FDA Approves the First Treatment for Neurofibromatosis 1
In a major breakthrough, the Food and Drug Administration has approved a treatment for a genetic disorder called neurofi ...
MAY 13, 2020
Drug Discovery & Development
MAY 13, 2020
Approved Treatment for RET-mutant Cancers
A drug was recently approved for treating three types of RET-mutant cancers: 1) non-small cell lung cancer (NSCLC) 2) ad ...
Loading Comments...